TmPSMA-02 / Gilead - LARVOL DELTA

TmPSMA-02 in mCRPC (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: University of Pennsylvania | Active, not recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

TmPSMA-02 in mCRPC (clinicaltrials.gov) - P1 | N=8 | Active, not recruiting | Sponsor: University of Pennsylvania | Recruiting ➔ Active, not recruiting | N=18 ➔ 8

Enrollment change • Enrollment closed • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

TmPSMA-02 in mCRPC (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: University of Pennsylvania | Not yet recruiting ➔ Recruiting

Enrollment open • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor

TmPSMA-02 in mCRPC (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: University of Pennsylvania

Metastases • New P1 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1/2 | N=1 | Terminated | Sponsor: Tceleron Therapeutics, Inc. | N=114 ➔ 1 | Trial completion date: Jan 2032 ➔ May 2023 | Active, not recruiting ➔ Terminated | Trial primary completion date: Jun 2028 ➔ May 2023; Study was stopped Sponsor discretion. No patients were dosed.

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Analyses of severe immune-mediated toxicity in patients with advanced mCRPC treated with a PSMA-targeted armored CAR T-cells (SITC 2022) - P1 | "Background We previously reported preliminary safety and efficacy results from a multi-center Phase 1 trial of CART-PSMA-TGFβRDN T-cells (TmPSMA-01; NCT04227275 ) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)...Knowledge gained from these studies supported the development of a next-generation PSMA-targeting CAR, TmPSMA-02, to improve safety while maintaining anti-tumor activity and will be explored in a multi-center, Ph1/2 trial for pts with mCRPC...The clinical study protocol and the informed consent form (ICF) were both reviewed and approved by the properly chartered IRBs and Independent Ethics Committee before the study commenced. Patients enrolled in the study underwent the appropriate Screening procedures only after providing the appropriate written consent using the approved ICF for this study."

CAR T-Cell Therapy • Clinical • Oncology • Prostate Cancer • CD2 • CSF2 • IL18 • IL2 • IL6 • TGFB1

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1/2 | N=114 | Active, not recruiting | Sponsor: Tmunity Therapeutics | Recruiting ➔ Active, not recruiting

Enrollment closed • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - P1/2 | N=114 | Recruiting | Sponsor: Tmunity Therapeutics | Not yet recruiting ➔ Recruiting

Enrollment open • Gastrointestinal Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CAST